Rybelsus and GI side effects: what 3 days actually tells you

What did @tanyalivingston13 actually say?

Tanya said that after three days on Rybelsus (oral semaglutide), she ended up hospitalized with vomiting of green bile lasting over 24 hours, cold sweats, and a lupus flare. She also said the same thing happened with "the majourno" (almost certainly Mounjaro, tirzepatide). Her conclusion: GLP-1 medications are "just not going to be the right thing" for her given her gastrointestinal issues and lupus.

To be fair to her, she is not claiming this happens to everyone. She is sharing her own experience and explicitly wishes others good luck with GLP-1s. That framing matters. But 42,000 people watched this, and the takeaway many will absorb is that GLP-1 medications cause hospitalization. That deserves a closer look.

Does the science back this up?

GLP-1 receptor agonists do slow gastric emptying. That is not a side effect, it is part of how they work. For most people this causes nausea and occasional vomiting that fades over weeks. For someone who already has gastroparesis, this can get genuinely dangerous.

Tanya mentions she has "a lot of gastrointestinal issues," and she references both gastroparesis and gastritis in the video caption. The American Gastroenterological Association issued a clinical alert in 2023 flagging that GLP-1 agonists can significantly worsen gastroparesis symptoms in patients who already have delayed gastric emptying. Bharucha et al. (2022, Gastroenterology) documented cases where semaglutide precipitated severe gastroparesis exacerbations requiring hospitalization. Vomiting of bile (bilious emesis) over 24 hours is consistent with a severe gastroparesis episode, not just typical GLP-1 nausea. That is a meaningful clinical distinction.

The lupus connection is less clear-cut. There is no strong published evidence that semaglutide directly triggers lupus flares. Severe physiological stress, like protracted vomiting and dehydration, can precipitate autoimmune flares. That is a more plausible mechanistic explanation than a direct drug-lupus interaction.

What did they get wrong (or right)?

She got the core personal experience right: pre-existing gastroparesis is a genuine contraindication for GLP-1 therapy, and her hospitalization is clinically plausible given that history. That is not an overreaction or misinformation. That is a real risk that prescribers are supposed to screen for.

Where it gets murkier is the implied causation with lupus. Saying the medication "put" her in the hospital and triggered her lupus rash conflates two things. The vomiting causing dehydration and physiological stress, which then worsened her lupus, is different from the drug directly causing a lupus flare. The distinction matters because it changes what the risk actually is and who it applies to.

She also misidentifies Mounjaro as "the majourno," which is just a pronunciation issue, not a factual error. But it is worth noting: Mounjaro (tirzepatide) and Rybelsus (oral semaglutide) work on overlapping but distinct receptor pathways. Having a severe reaction to both is notable and does suggest her underlying GI condition is the primary driver, not a quirk of one specific drug.

What should you actually know?

Pre-existing gastroparesis is listed as a condition requiring caution before starting GLP-1 therapy in prescribing guidelines. Davies et al. (2021, Diabetes Care) and the prescribing information for semaglutide both flag delayed gastric emptying as a relevant consideration. If you have known gastroparesis, this conversation with your prescriber is not optional, it is required before starting.

The broader lesson here is about informed prescribing, not about GLP-1 medications being broadly dangerous. For patients without gastroparesis, the GI side effect profile is generally manageable. The SUSTAIN and PIONEER trials showed that nausea and vomiting occur in roughly 15-20% of semaglutide users and typically resolve within 4-8 weeks with proper dose titration.

• Bilious vomiting for over 24 hours is not normal GLP-1 nausea. That warrants emergency evaluation.
• Lupus patients taking any new medication should have a plan for monitoring flares. Dehydration from any cause can trigger autoimmune activity.
• Tanya's decision to stop GLP-1s is reasonable given her specific medical history. It is not a universal recommendation.